Johnson Matthey (JMAT) Rating Reiterated by UBS Group
Johnson Matthey (LON:JMAT)‘s stock had its “sell” rating reiterated by equities research analysts at UBS Group in a note issued to investors on Thursday, investing.thisismoney.co.uk reports.
A number of other research firms also recently weighed in on JMAT. Deutsche Bank restated a “buy” rating on shares of Johnson Matthey in a report on Monday, July 16th. Liberum Capital restated a “buy” rating and set a GBX 4,000 ($52.27) price target on shares of Johnson Matthey in a report on Thursday, July 26th. Berenberg Bank restated a “buy” rating and set a GBX 4,300 ($56.19) price target on shares of Johnson Matthey in a report on Tuesday, July 3rd. Finally, Credit Suisse Group restated an “outperform” rating on shares of Johnson Matthey in a report on Thursday, August 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of GBX 3,962.50 ($51.78).
Johnson Matthey stock opened at GBX 2,914 ($38.08) on Thursday. Johnson Matthey has a 1-year low of GBX 2,681 ($35.03) and a 1-year high of GBX 3,511 ($45.88).
Johnson Matthey Company Profile
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
Read More: Growth Stocks
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.